ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - ALX Oncology has had a significant year, with seven different data sets read out, indicating strong progress in its clinical programs [2] - The company is focused on developing two clinical stage programs, evorpacept and ALX2004, which are differentiated within their class [2] - Evorpacept targets CD47, a crucial element in the immune system and oncology, which has historically been challenging to address [2]